


Fig. 1


Fig. 2a



Fig. 2b

Fig. 3

Sheet 5/28





Fig. 4


Fig. 5


Fig. 6a




Fig. 6c


Fig. 7


Fig. 8





Fig. 9a


Fig. 9b


Fig. 10


Fig. 11


Fig. 12





Fig. 13a**Fig. 13b**

Fig. 13c**Activity of Compounds against H226 Cells**

Compound	Doxorubicin	Tubulysin D	(I-5)	(I-6)	(I-7)
EC ₅₀ (nM)	115.4	0.05	19.5	9.9	15.4

Fig. 13d**Activity of Compounds against 786-O Cells**

Compound	Doxorubicin	Tubulysin D	(I-5)	(I-6)	(I-7)
EC ₅₀ (nM)	68.9	0.02	22.9	22.8	12.5



Fig. 14**Fig. 15****In Vivo Activity of Conjugates Against OVCAR3 Xenografts**



Fig. 16a**Fig. 16b**



Fig. 17a**Fig. 17b**



Fig. 18a**Fig. 18b**



Fig. 19a**Fig. 19b**


Fig. 20





Fig. 21


Fig. 22


Fig. 23

Fig. 24